Le Lézard
Classified in: Health, Science and technology, Business
Subject: TNM

Candor Announces Acquisition of Tenex


ROME, Ga. and NEW YORK, Dec. 16, 2017 /PRNewswire/ -- Candor, a technology and marketplace company specializing in pairing consumers with top health plans, announces the acquisition of Tenex, a comprehensive software development company. Candor is strengthened by the transaction and now has the ability to enhance technological support.

Candor enables access to truly flexible benefits and wellness solutions based on the specific needs of consumers and offers Prosper Benefitstm at the True Cost of Caretm. The Candor app simplifies the enrollment process and automates the user experience.

John Good, COO of Candor, explains, "We demonstrate the True Cost of Care. In other words, there are healthcare plans that have higher negotiated rates for the same procedures. These plans, which we eliminate, are masked by similar copays, deductibles and out-of-pocket expenses. We feel they are deceptive and strive to present plans with integrity."

Tenex builds scalable, maintainable, robust code. They have drawn on the successes of their experiences at enterprises (like Vistaprint and Amazon) and startups (like Financial Diligence Networks) to develop a program that maximizes the ability to build a successful product.

Josh Jordan, CEO of Tenex says, "Tenex has always been about solving the hardest problems in the business. Candor is out to change the world through technology, and #democratizehealthinsurance by changing how people think about their coverage. That demands a phenomenal product. Keeping quality impossibly high, while iterating quickly is paramount. This is what we do every day, and we feel it is a perfect fit! We're still Tenex developers and we always will be, but now we get to come along for the journey with our new family at Candor."

About Candor

Candor is a technology and marketplace company providing powerful analytics, tools, and methodologies to benefit Agencies, Carriers, and Healthcare Providers. We are the health companion that enables Americans to access the information and solutions they need to achieve a state of complete independence, success and wellbeing.

For more information visit https://candor.insurance.

About Tenex
Tenex solves the hardest technology problems the industry has to offer. We build scalable, maintainable, robust code that solves business problems. We aren't interested in perfect design or perfect code, we're interested in adding value.

For more information visit https://www.crunchbase.com/organization/tenex-developers.

Candor PR contact
Merissa Rood
[email protected]

SOURCE Candor USA


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: